145 related articles for article (PubMed ID: 25031973)
1. Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
Kurtin S; Knop CS; Milliron T
J Adv Pract Oncol; 2012 Nov; 3(6):406-10. PubMed ID: 25031973
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
3. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Mu SD; Ai LS; Qin Y; Hu Y
Curr Med Sci; 2018 Feb; 38(1):43-50. PubMed ID: 30074150
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.
Ng P; Incekol D; Lee R; Paisley E; Dara C; Brandle I; Kaufman M; Chen C; Trudel S; Tiedemann R; Reece D; Kukreti V
J Oncol Pharm Pract; 2015 Aug; 21(4):285-92. PubMed ID: 24781451
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
8. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.
Ye Z; Chen J; Xuan Z; Yang W; Chen J
Drug Des Devel Ther; 2019; 13():1707-1716. PubMed ID: 31190749
[No Abstract] [Full Text] [Related]
11. Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses.
Martin JR; Beegle NL; Zhu Y; Hanisch EM
J Adv Pract Oncol; 2015; 6(4):308-18. PubMed ID: 26705492
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS
Ann Pharmacother; 2013 Sep; 47(9):1136-42. PubMed ID: 24259728
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma.
Wang L; Wang KF; Chang BY; Chen XQ; Xia ZJ
Asian Pac J Cancer Prev; 2015; 16(5):2093-8. PubMed ID: 25773856
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.
Mateos MV; San Miguel JF
Ther Adv Hematol; 2012 Apr; 3(2):117-24. PubMed ID: 23556118
[TBL] [Abstract][Full Text] [Related]
15. Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma.
Raedler L
Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):135-40. PubMed ID: 26629279
[No Abstract] [Full Text] [Related]
16. Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F; Srinivasan A; Vallance G; Moore S; Kothari J; Ramasamy K
PLoS One; 2018; 13(12):e0208920. PubMed ID: 30540831
[TBL] [Abstract][Full Text] [Related]
17. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Int J Hematol; 2013 Dec; 98(6):694-701. PubMed ID: 24249047
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Rizzello I; Cavo M; Dozza L; Rivolti E; Petrucci MT; De Stefano V; Antonioli E; Tosi P; D'Agostino M; Morè S; Gozzetti A; Cea M; Barbato S; Tacchetti P; Pantani L; Mancuso K; Rocchi S; De Cicco G; Fusco A; Zamagni E
Leuk Lymphoma; 2021 Aug; 62(8):1897-1906. PubMed ID: 33733993
[TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
